Abatacept Launch Will Be Bolstered By Unmet Need In RA Market – Bristol

Bristol is focusing on rheumatoid arthritis patients who do not respond to TNF inhibitors. The initial launch material will come from Bristol's Syracuse, N.Y. facility; the company will rely on contract manufacturer Lonza to provide additional supply once a supplemental BLA is approved.